The Patent Finder

Eb IP Lybrido B.V.

Also on record
Records under this name other than the patents Eb IP Lybrido B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Eb IP Lybrido B.V.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,669,242Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
Lapsed on the fee record
Ended Mar 11, 2026 · USPTO record
Lapsed on the fee recordEnded Mar 11, 2026USPTO record
US 8,648,060Use of 3-alpha-androstanediol in combination with a 5-HT1a agonist, in the treatment of sexual dysfunction
Lapsed on the fee record
Ended Feb 11, 2026 · USPTO record
Lapsed on the fee recordEnded Feb 11, 2026USPTO record
US 8,575,139Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction
Lapsed on the fee record
Ended Nov 5, 2025 · USPTO record
Lapsed on the fee recordEnded Nov 5, 2025USPTO record
US 9,737,548Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
Lapsed on the fee record
Ended Aug 22, 2025 · USPTO record
Lapsed on the fee recordEnded Aug 22, 2025USPTO record
US 9,192,669Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
Term ended
Term ended Jun 30, 2025 · USPTO record
Term endedTerm ended Jun 30, 2025USPTO record
US 9,700,566Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
Term ended
Ended no later than May 11, 2025 · USPTO record
Term endedEnded no later than May 11, 2025USPTO record
US 10,441,592Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
Term ended
Ended no later than May 11, 2025 · USPTO record
Term endedEnded no later than May 11, 2025USPTO record
US 9,333,203Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
Lapsed on the fee record
Ended May 10, 2024 · USPTO record
Lapsed on the fee recordEnded May 10, 2024USPTO record
US 9,211,334Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
Lapsed on the fee record
Ended Dec 15, 2023 · USPTO record
Lapsed on the fee recordEnded Dec 15, 2023USPTO record
US 10,314,848Use of testosterone and a 5-HT1A agonist in the treatment of sexual dysfunction
Lapsed on the fee record
Ended Jun 11, 2023 · USPTO record
Lapsed on the fee recordEnded Jun 11, 2023USPTO record
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited